Natixis Asset Management acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the third quarter, Holdings Channel reports. The firm acquired 35,634 shares of the company’s stock, valued at approximately $848,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. First American Trust FSB raised its position in Boston Scientific Corporation by 33.3% in the third quarter. First American Trust FSB now owns 134,341 shares of the company’s stock worth $3,197,000 after buying an additional 33,588 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Boston Scientific Corporation by 14.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 613,289 shares of the company’s stock worth $14,596,000 after buying an additional 75,768 shares during the period. Bank of Montreal Can acquired a new position in Boston Scientific Corporation during the second quarter worth $13,309,000. Evercore Trust Company N.A. raised its position in Boston Scientific Corporation by 0.3% in the third quarter. Evercore Trust Company N.A. now owns 12,385,712 shares of the company’s stock worth $294,780,000 after buying an additional 33,379 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its position in Boston Scientific Corporation by 29.5% in the third quarter. Oregon Public Employees Retirement Fund now owns 329,557 shares of the company’s stock worth $7,843,000 after buying an additional 75,011 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) traded up 1.28% during midday trading on Friday, reaching $23.82. 9,486,079 shares of the company were exchanged. The firm has a market capitalization of $32.44 billion, a PE ratio of 449.43 and a beta of 1.09. The company has a 50-day moving average of $21.55 and a 200 day moving average of $22.84. Boston Scientific Corporation has a 52 week low of $15.67 and a 52 week high of $24.79.

Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Wednesday, October 26th. The company reported $0.27 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.27. The business earned $2.11 billion during the quarter, compared to the consensus estimate of $2.07 billion. Boston Scientific Corporation had a return on equity of 23.25% and a net margin of 0.99%. The business’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.24 EPS. Equities analysts predict that Boston Scientific Corporation will post $1.10 earnings per share for the current year.

WARNING: This article was first published by Watch List News and is the propert of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The correct version of this article can be viewed at http://www.watchlistnews.com/natixis-asset-management-acquires-shares-of-35634-boston-scientific-corporation-bsx/1060781.html.

BSX has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Boston Scientific Corporation from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Tuesday, October 4th. Citigroup Inc. raised their price target on shares of Boston Scientific Corporation from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, October 6th. Royal Bank Of Canada reissued an “outperform” rating and set a $28.00 price target on shares of Boston Scientific Corporation in a research report on Friday, October 14th. TheStreet raised shares of Boston Scientific Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, October 26th. Finally, Vetr raised shares of Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating and set a $23.52 price objective on the stock in a research report on Monday, December 5th. Six investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $25.75.

In related news, EVP Timothy A. Pratt sold 26,726 shares of the business’s stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $20.48, for a total transaction of $547,348.48. Following the completion of the sale, the executive vice president now directly owns 260,430 shares in the company, valued at $5,333,606.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy A. Pratt sold 6,195 shares of the business’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $22.24, for a total value of $137,776.80. Following the sale, the executive vice president now owns 231,273 shares of the company’s stock, valued at $5,143,511.52. The disclosure for this sale can be found here. Insiders own 1.31% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.